# Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)

> **NCT04927702** · NA · TERMINATED · sponsor: **Acera Surgical, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Diabetic Foot Ulcer
- Venous Leg Ulcer

## Interventions

- **DEVICE:** Synthetic Hybrid-Scale Fiber Matrix
- **DEVICE:** Standard of Care
- **DEVICE:** Living Cellular Skin Substitute

## Key facts

- **NCT ID:** NCT04927702
- **Lead sponsor:** Acera Surgical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-19
- **Primary completion:** 2024-07-15
- **Final completion:** 2024-08-01
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Study was terminated due to slow enrollment
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04927702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04927702, "Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT04927702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*